Journal
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
Volume 105, Issue 21, Pages 1667-1670Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djt269
Keywords
-
Categories
Funding
- French Institut National du Cancer (grant PHRC GASTRIC)
- Clinical Research Support Unit
- Epidemiological and Clinical Research Information Network
- GlaxoSmithKline
Ask authors/readers for more resources
The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval [CI] = 0.852 to 0.854). The R-2 between treatment effects on PFS and on OS was 0.61 (95% CI = 0.04 to 1.00). Treatment effects on PFS and on OS were only moderately correlated, and we could not confirm the validity of PFS as a surrogate endpoint for OS in advanced/recurrent gastric cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available